148 related articles for article (PubMed ID: 17803960)
21. A highly sensitive detection method for somatic mutations in p53 gene.
Sato T; Sato A; Ishihara H; Konishi K
Rinsho Byori; 2003 Feb; 51(2):98-106. PubMed ID: 12690626
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer.
Miyake M; Sugano K; Sugino H; Imai K; Matsumoto E; Maeda K; Fukuzono S; Ichikawa H; Kawashima K; Hirabayashi K; Kodama T; Fujimoto H; Kakizoe T; Kanai Y; Fujimoto K; Hirao Y
Cancer Sci; 2010 Jan; 101(1):250-8. PubMed ID: 19843069
[TBL] [Abstract][Full Text] [Related]
23. Comparison of a PNA clamp PCR and an ARMS/Scorpion PCR assay for the detection of K-ras mutations.
Nordgård O; Oltedal S; Janssen EA; Gilje B; Kørner H; Tjensvoll K; Smaaland R
Diagn Mol Pathol; 2012 Mar; 21(1):9-13. PubMed ID: 22306670
[TBL] [Abstract][Full Text] [Related]
24. H-ras mutation detection in bladder cancer by COLD-PCR analysis and direct sequencing.
Wang AX; Chang JW; Li CY; Liu K; Lin YL
Urol Int; 2012; 88(3):350-7. PubMed ID: 22433386
[TBL] [Abstract][Full Text] [Related]
25. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: a novel approach using peptide nucleic acid-mediated, real-time PCR clamping.
Kim EJ; Yan C; Ha YS; Jeong P; Yi Kim I; Moon SK; Choi YH; Kim WJ
Urol Oncol; 2012 Sep; 30(5):673-9. PubMed ID: 20884250
[TBL] [Abstract][Full Text] [Related]
26. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
[TBL] [Abstract][Full Text] [Related]
27. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
[TBL] [Abstract][Full Text] [Related]
28. SNPs detection by a single-strand specific nuclease on a PNA zip-code microarray.
Mun HY; Girigoswami A; Jung C; Cho DY; Park HG
Biosens Bioelectron; 2009 Feb; 24(6):1706-11. PubMed ID: 18930386
[TBL] [Abstract][Full Text] [Related]
29. Detection of apolipoprotein B mRNA editing by peptide nucleic acid mediated PCR clamping.
Zhong S; Nguyen NY; Eggerman TL
Biochem Biophys Res Commun; 1999 Jun; 259(2):311-3. PubMed ID: 10362504
[TBL] [Abstract][Full Text] [Related]
30. Activation of RAS family genes in urothelial carcinoma.
Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
[TBL] [Abstract][Full Text] [Related]
31. COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing.
Li J; Makrigiorgos GM
Biochem Soc Trans; 2009 Apr; 37(Pt 2):427-32. PubMed ID: 19290875
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous identification of mutations by dual-parameter multiplex hybridization in peptide nucleic acid-containing virtual arrays.
Igloi GL
Genomics; 2001 Jun; 74(3):402-7. PubMed ID: 11414769
[TBL] [Abstract][Full Text] [Related]
33. Usefulness of droplet digital PCR and Sanger sequencing for detection of FGFR3 mutation in bladder cancer.
Borkowska EM; Traczyk-Borszyńska M; Kutwin P; Pietrusiński M; Jabłonowski Z; Borowiec M
Urol Oncol; 2019 Dec; 37(12):907-915. PubMed ID: 31377167
[TBL] [Abstract][Full Text] [Related]
34. FIT-probes in real-time PCR.
Socher E; Seitz O
Methods Mol Biol; 2008; 429():187-97. PubMed ID: 18695967
[TBL] [Abstract][Full Text] [Related]
35. Bladder cancer: novel molecular characteristics, diagnostic, and therapeutic implications.
Kompier LC; van Tilborg AA; Zwarthoff EC
Urol Oncol; 2010; 28(1):91-6. PubMed ID: 20123356
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer.
Pandith AA; Hussain A; Khan MS; Shah ZA; Wani MS; Siddiqi MA
Asian Pac J Cancer Prev; 2016; 17(6):2787-93. PubMed ID: 27356691
[TBL] [Abstract][Full Text] [Related]
37. Detection of K-ras mutations in azoxymethane-induced aberrant crypt foci in mice using LNA-mediated real-time PCR clamping and mutant-specific probes.
Hu Y; Le Leu RK; Young GP
Mutat Res; 2009; 677(1-2):27-32. PubMed ID: 19442760
[TBL] [Abstract][Full Text] [Related]
38. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.
Serizawa RR; Ralfkiaer U; Steven K; Lam GW; Schmiedel S; Schüz J; Hansen AB; Horn T; Guldberg P
Int J Cancer; 2011 Jul; 129(1):78-87. PubMed ID: 20824703
[TBL] [Abstract][Full Text] [Related]
39. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
[TBL] [Abstract][Full Text] [Related]
40. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer.
Yu J; Zhu T; Wang Z; Zhang H; Qian Z; Xu H; Gao B; Wang W; Gu L; Meng J; Wang J; Feng X; Li Y; Yao X; Zhu J
Clin Cancer Res; 2007 Dec; 13(24):7296-304. PubMed ID: 18094410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
